---
document_datetime: 2023-09-21 21:48:37
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kanjinti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: kanjinti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.909266
conversion_datetime: 2025-12-31 04:17:16.528282
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## KANJINTI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0022               | Renewal of the marketing authorisation. | 15/12/2022                          | 03/02/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of KANJINTI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/3010/ 202109   | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2022   | n/a        |             | PRAC Recommendation - maintenance   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| IB/0019/G            | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 02/12/2021   | n/a        |             |                                     |
| IB/0020/G            | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                      | 18/11/2021   | 16/12/2021 | SmPC and PL |                                     |

<div style=\"page-break-after: always\"></div>

| IB/0018   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 23/08/2021   | 16/12/2021   | SmPC and PL                      | To update sections 4.6 and 6.6 of the SmPC and healthcare professionals information of the PL to update section of Fertility, pregnancy and lactation, for clarity purposes and Special precautions for disposal and other handling, to provide clarity, following assessment of the same change for the reference product   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 15/01/2021   | 16/12/2021   | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                              |
| IB/0016   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                            | 18/12/2020   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                              |
| IB/0015   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                               | 29/06/2020   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                              |
| IA/0014   | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                             | 19/12/2019   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                              |
| IB/0013   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                          | 06/11/2019   | 27/10/2020   | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| PSUSA/3010/ 201809   | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                             | 29/05/2019   | 25/07/2019   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3010/201809.   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient          | 26/04/2019   | n/a          |               |                                                                                                                                             |
| IB/0010              | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                           | 25/04/2019   | n/a          |               |                                                                                                                                             |
| N/0011               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                      | 23/04/2019   | 25/07/2019   | PL            |                                                                                                                                             |
| IB/0009              | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                          | 15/03/2019   | n/a          |               |                                                                                                                                             |
| IB/0008              | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                          | 07/02/2019   | n/a          |               |                                                                                                                                             |
| II/0006/G            | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a | 17/01/2019   | 25/07/2019   | Annex II      |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB   |            |            |                 | biological/immunological   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------|
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                     | 14/09/2018 | 25/07/2019 | SmPC and PL     |                            |
| IB/0003   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                 | 31/08/2018 | n/a        |                 |                            |
| IAIN/0004 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                           | 17/08/2018 | 25/07/2019 | Annex II and PL |                            |
| IB/0002/G | This was an application for a group of variations. B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                 | 20/07/2018 | 25/07/2019 | SmPC            |                            |

<div style=\"page-break-after: always\"></div>

|         | variation B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product   |            |     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001 | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                             | 13/07/2018 | n/a |